🇺🇸 FDA

Company profile · Sponsor

Novo

Novo Nordisk A/S

EBE6030 · EMA pharma Bagsværd, DK
Pipeline
24
Drugs
0
Patents
0

Quick answer

Novo (EBE6030) is a pharma company. headquartered in Bagsværd, DK. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EBE6030
Exchange EMA
Company type pharma
Headquarters Bagsværd, DK

Pipeline (24)

Search pipeline →

  1. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290

    Novo

    haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

    phase 3 small molecule active

    1 trial

  2. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290

    Novo

    Haemophilia A or B with or without inhibitors

    phase 3 small molecule active

    1 trial

  3. Concizumab C 40 mg/mL PDS290, Concizumab C 100 mg/mL PDS290

    Novo

    haemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

    phase 3 small molecule active

    1 trial

  4. Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity

    Novo

    Overweight and obesity

    phase 3 other active

    1 trial

  5. Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg

    Novo

    sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  6. Etavopivat A 200 mg

    Novo

    Sickle Cell Disease and Thalassaemia

    phase 3 small molecule active

    1 trial

  7. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    Novo

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  8. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Ozempic 2 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    Novo

    Participants with T2D and overweight

    phase 3 small molecule active

    1 trial

  9. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, insulin icodec 700 U/mL PDS290

    Novo

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  10. Liraglutide placebo, Saxenda 6 mg/mL solution for injection in pre-filled pen

    Novo

    Obesity

    phase 3 small molecule active

    1 trial

  11. Mounjaro 5 mg solution for injection in pre-filled pen, cagrilintide semaglutide, cagrilintide semaglutide, Mounjaro 2.5 mg solution for injection in pre-filled pen, cagrilintide semaglutide

    Novo

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  12. NNC0487-0111 B 10142, NNC0487-0111 B 10141, Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10144

    Novo

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  13. NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10146, NNC0487-0111 B 10144

    Novo

    Obesity

    phase 3 small molecule active

    1 trial

  14. NNC0487-0111 B 10142, Placebo (NNC0487-0111), NNC0487-0111 B 10143, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10141

    Novo

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  15. NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

    Novo

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  16. NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141

    Novo

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  17. NNC0487-0111 B 10146, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10141

    Novo

    Obesity

    phase 3 small molecule active

    1 trial

  18. NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10145, NNC0487-0111 B 10144

    Novo

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  19. Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

    Novo

    Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

    phase 3 small molecule active

    1 trial

  20. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    Novo

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  21. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide placebo, solution for injection in 1.5 mL pre-filled PDS290 pen injector

    Novo

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  22. Placebo (ziltivekimab), ziltivekimab

    Novo

    Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

    phase 3 small molecule active

    1 trial

  23. Placebo (ziltivekimab), ziltivekimab

    Novo

    Acute myocardial infarction

    phase 3 small molecule active

    1 trial

  24. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    Novo

    Obesity

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Novo?

Novo (EBE6030) is a pharma company. headquartered in Bagsværd, DK. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Novo sponsor?

We track 24 ClinicalTrials.gov-linked programs for Novo, including Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Novo company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.